Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical development, and safety testing services. It is valued at a market cap of $7.6 billion. Companies worth $2 billion or more are typically classified as “mid-cap stocks,” and CRL fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the diagnostics & research industry. By partnering with global research institution ...

It has been about a month since the last earnings report for Charles River Laboratories (CRL) . Shares have lost about 6.8% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Charles River due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Charles River Laboratories International, Inc. before ...

Question-and-Answer SessionSo with that, I guess we can start on the overall demand environment as you're thinking about your transition and giving the keys over, walk us through where you feel like the business is now from a jump-off perspective? How much more investment or changes might need to be made to catch some of the growing tailwinds that you see within the business?James FosterChairman, President & CEO Yes. I think it's -- I mean the demand has been so tightly tied to biotech funding. So we've alw ...

Charles River Laboratories (NYSE:CRL) FY Conference March 10, 2026 10:00 AM ET Company ParticipantsJames C. Foster - Chairman, President and CEOConference Call ParticipantsLuke Sergott - Director and Equity Research AnalystLuke SergottSergott from Barclays. I cover life science tools and diagnostic. With me, it's my pleasure, Jim Foster, CEO of Charles River. This is probably his first fireside chat I think you've ever done, so this is gonna be some learning curve here. Seriously, thank you. It's a pleasure ...

Ariel Investments, an investment management company, released its "Ariel Appreciation Fund" fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund advanced +3.04% in the fourth quarter of 2025, outperforming the Russell Midcap Value Index's +1.42% and the Russell Midcap Index's +0.16% returns as U.S. equities posted a modest gain to cap a third consecutive year of double-digit returns despite earlier volatility, including a sharp spring sell-off, a prolonged government sh ...

分组1 - Invesco Small Cap Value Fund reported a quarterly return of 6.79% in Q4 2025, outperforming the Russell 2000 Value Index which returned 3.26% [1] - For the full year, the fund achieved a return of 17.64%, compared to 12.59% for the Russell 2000 Value Index [1] - The fund's performance was bolstered by stock selection in the Information Technology sector, contributing approximately 2.90% to relative performance, while health care and financials detracted [1] 分组2 - Charles River Laboratories International, Inc. (NYSE:CRL) is a leading contract research organization that supports drug discovery, development, and manufacturing for pharmaceutical and biotechnology companies [3] - The stock of Charles River Laboratories had a one-month return of -2% and traded between $91.86 and $228.88 over the last 52 weeks, closing at approximately $179.58 per share with a market capitalization of about $8.86 billion [2] - Slower spending on biotech and pharma R&D has been a headwind for Charles River Laboratories, presenting an opportunity for investment at an attractive discount to intrinsic value [3] 分组3 - At the end of Q4 2025, 53 hedge fund portfolios held shares of Charles River Laboratories, an increase from 50 in the previous quarter [5] - Despite the potential of Charles River Laboratories, there is a belief that some AI stocks may offer greater promise for higher returns in a shorter time frame [5]

Core Insights - The company is undergoing significant leadership changes with Jim Foster retiring after over 30 years as CEO, marking a new chapter for the organization [1] - Birgit Girshick has been appointed as the new CEO, expressing gratitude for Jim Foster's mentorship and contributions to the company's growth [2] - The company is recognized as an industry leader, involved in over 80% of all drugs approved by the FDA, highlighting its critical role in the pharmaceutical industry [2][3]

Summary of Charles River Laboratories FY Conference Call Company Overview - **Company**: Charles River Laboratories (NYSE: CRL) - **New Leadership**: Birgit Girshick is the incoming CEO, succeeding Jim Foster after over 30 years in the role [4][3] Strategic Initiatives - **Acquisitions**: Two acquisitions were made to enhance supply chain integration and alternative methods for Next-Generation Sequencing [5] - **Divestitures**: Agreements were signed for divesting CDMO and Cell Solutions businesses, as well as some European discovery services [6] - **Digital Transformation**: Over $300 million in cumulative cost reductions achieved, with ongoing efforts to modernize operations [7] Market Trends and Client Insights - **Funding Environment**: Positive trends observed in biotech proposal and bookings since summer, with improved funding conditions for companies with strong programs [9][10] - **Client Confidence**: Clients are optimistic about funding and accelerating drug development, with a net book-to-bill ratio above 1 in Q4 2025 [11][12] Regulatory Environment - **FDA and NIH Impact**: Minimal disruption noted from FDA turnover; NIH funding has stabilized, impacting academic clients but not significantly affecting overall business [13][14] AI in Drug Development - **Client Discussions**: Clients are exploring AI's potential to accelerate drug discovery, with around 150 AI-assisted drug programs currently in the clinic [18][19] - **Long-Term Perspective**: AI is viewed as an evolutionary tool rather than a revolutionary change, with expectations for gradual improvements in efficiency [20][22] Financial Outlook - **Share Repurchase Plans**: Stock repurchases are expected in 2026 due to stock price fluctuations and ongoing capital allocation assessments [28] - **Patent Cliff Navigation**: Pharma companies are prepared for upcoming patent expirations, having already restructured and reprioritized their drug programs [29] Segment Performance - **Manufacturing Segment**: Expected mid-single-digit growth, with strong performance in microbial solutions and biologics testing [46][48] - **CRADL Business**: Demand from early-stage biotech clients remains stable but lacks growth momentum; reliant on increased biotech funding for future growth [39][40] Geographic Expansion - **China Market**: China accounts for 15% of total revenue from research models; potential for expanding DSA services is under evaluation [42][43] Conclusion - **Focus Areas**: The primary focus is on returning to growth, executing modernization strategies, and enhancing shareholder value [50]

Core Viewpoint - Charles River Laboratories has raised its 2026 profit forecast following the sale of underperforming assets to IQVIA and GI Partners, aiming to focus on more synergistic business areas [1][6]. Group 1: Asset Sales - The company will sell certain European assets within its drug discovery business to IQVIA for approximately $145 million, with potential additional payments of up to $10 million [3]. - Charles River will also divest its contract development and manufacturing (CDMO) and cell solutions units to GI Partners, which generated $143 million in revenue in 2025 [5]. Group 2: Financial Impact - The divestitures are expected to reduce reported 2026 revenue by just over $200 million but will increase the adjusted operating margin by at least 100 basis points [6]. - The adjusted per share profit for 2026 is now projected to be between $10.80 and $11.30, reflecting an increase of 10 cents at both the lower and upper ends from the previous forecast [6]. Group 3: Market Context - The asset sales occur as the company anticipates improved demand for its services, with more proposals and fewer cancellations from drugmakers, following a period of reduced activity due to U.S. government drug price negotiations [2]. - Biotech clients are experiencing an increase in funding since 2025, indicating a recovery from the post-pandemic downturn [2].

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...